Top

Supportive Care in Cancer

Published in:

01-10-2013 | Review Article

Cancer-related fatigue in the elderly

Authors: A. Giacalone, D. Quitadamo, E. Zanet, M. Berretta, M. Spina, U. Tirelli

Published in: Supportive Care in Cancer | Issue 10/2013

Abstract

Purpose

Cancer is a disease of the elderly: 60 % of tumours occur in patients aged 65 years or older. Cancer-related fatigue is a common symptom experienced by cancer patients and cancer survivors that profoundly affects all aspects of the quality of life. Although it has been estimated that up to 70 % of elderly with cancer experience fatigue, this symptom is still largely ignored in ageing population.

Methods

We performed a systematic review of the literature identified by MEDLINE.

Results

The relationship between ageing process and pathogenesis of cancer-related fatigue is still not fully understood.

Conclusions

Ageing is associated with an increased prevalence of chronic diseases, decreased functional reserve in multiple organ systems and enhanced susceptibility to stress. Ageing and the concomitant presence of a condition of frailty may predispose to the presence of fatigue. Nevertheless, only few studies have to date specifically assessed the impact of fatigue in the geriatric population. Since cancer-related fatigue is a peculiarly debilitating condition characteristic of elderly cancer patient population, we suggest the early recognition and thorough evaluation of the symptom fatigue, its co-existing causes (i.e. anaemia, mood disorders and sleep disturbances) and co-morbidities (i.e., endocrine disorders, metabolic, cardiovascular and liver diseases).

Available only for authorised users

Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology 12:369–377PubMed

Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4:1–10PubMed

National Comprehensive Cancer Network: Cancer-related fatigue, version 1.2012. http://www.nccn.org/professionals/physicians/PDF/fatigue.pdf. Accessed 4 Apr 2012

de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM (2004) Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 15:896–905PubMedCrossRef

Prue G, Rankin J, Allen J, Gracey J, Cramp F (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRef

Wu HS, McSweeney M (2007) Cancer-related fatigue: “It’s so much more than just being tired”. Eur J Oncol Nurs 11:117–125PubMedCrossRef

Yavuzsen T, Davis MP, Ranganathan VK, Walsh D, Siemionow V, Kirkova J et al (2009) Cancer-related fatigue: central or peripheral? J Pain Symptom Manage 38:587–596PubMedCrossRef

Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D et al (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6:448–455PubMed

Kuhnt S, Ernst J, Singer S, Rüffer JU, Kortmann RD, Stolzenburg JU et al (2009) Fatigue in cancer survivors: prevalence and correlates. Onkologie 32:312–317PubMedCrossRef

10.

Giacalone A, Spina M, Berretta M, Tirelli U (2012) Two types of fatigue in cancer patients. BJC 106:424PubMedCrossRef

11.

Curt GA (2001) Fatigue in cancer. Brit Med J 322:1560PubMedCrossRef

12.

Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91:822–828PubMed

13.

Nail LM (2004) My get up and go up and went: fatigue in people with cancer. JNCI Monogr 32:72–75CrossRef

14.

Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anaemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood 104:2263–2268PubMedCrossRef

15.

Denny SD, Kuchibhatla MN, Cohen HJ (2006) Impact of anaemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119:327–334PubMedCrossRef

16.

Extermann M, Chen H, Cantor AB, Corcoran MB, Meyer J, Grendys E et al (2002) Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 38:1466–1473PubMedCrossRef

17.

Balducci L (2010) Anemia, fatigue and aging. Transfus Clin Biol 17:375–381PubMedCrossRef

18.

Mercuriali F, Inghilleri G (2001) Treatment of anaemia in cancer patients: transfusion of rHuEPO. In: Marty M, Pecorelli S (eds) Fatigue and cancer. European School of Oncology Scientific Updates, 5. Elsevier, Amsterdam, pp 185–200

19.

Ferrucci L, Guralnik JM, Woodman RC, Bandinelli S, Lauretani F, Corsi AM et al (2005) Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 118:1288PubMedCrossRef

20.

Nemeth E, Tuttle MS, Powelson J, Donovan A, Ward DM, Ganz T et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093PubMedCrossRef

21.

Stabler SP (2008) Prevalence and mechanisms of B12 deficiency. In: Balducci L, Ershler WH, DeGaetano G (eds) Blood disorders in the elderly. University Press, Cambridge, pp 181–191

22.

Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A et al (2006) Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166:1380–1388PubMedCrossRef

23.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al. (2009) Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev CD007303

24.

Raison CL, Miller AH (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54:283–294PubMedCrossRef

25.

Mohile SG, Fan L, Reeve E, Mustian K, Peppone L, Janelsins M et al (2011) Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol 29:1458–1464PubMedCrossRef

26.

Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174PubMedCrossRef

27.

American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-Text Revision), 4th edn. APA, Washington

28.

Cohen-Cole SA, Brown FW, McDaniel JS (1993) Diagnostic assessment of depression in the medically ill. In: Stoudemire A, Fogel B (eds) Psychiatric care of the medical patient. Oxford University Press, New York, pp 53–70

29.

Reuter K, Härter M (2004) The concepts of fatigue and depression in cancer. Eur J Cancer Care 13:127–134CrossRef

30.

Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Program. J Clin Oncol 21:4635–4641PubMedCrossRef

31.

Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR et al (2007) Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 8:603–612PubMedCrossRef

32.

Fiorentino L, Ancoli-Israel S (2006) Insomnia and its treatment in women with breast cancer. Sleep Med Rev 10:419–429PubMedCrossRef

33.

Spiegel K, Leproult R, Van Cauter E (1999) Impact of sleep debt on metabolic and endocrine function. Lancet 354:1435–1439PubMedCrossRef

34.

Caufriez A, Moreno-Reyes R, Leproult R, Vertongen F, Van Cauter E, Copinschi G (2002) Immediate effects of an 8-h advance shift of the rest-activity cycle on 24-h profiles of cortisol. Am J Physiol Endocrinol Metab 282:E1147–E1153PubMed

35.

Rao A, Cohen HJ (2004) Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr 32:150–157PubMedCrossRef

36.

Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet 363:978–988PubMedCrossRef

37.

Swain MG (2000) Fatigue in chronic disease. Clin Sci 99:1–8PubMedCrossRef

38.

Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953–959PubMedCrossRef

39.

Andrews PL, Morrow GR, Hickok JT (2004) Mechanisms and models of fatigue associated with cancer and its treatment: Evidence of pre-clinical and clinical studies. In: Armes J, Krishnasamy M, Higginson I (eds) Fatigue in cancer. Oxford University Press, Oxford, pp 51–87

40.

Fernstrom JD, Fernstrom MH (2006) Exercise, serum free tryptophan, and central fatigue. J Nutr 136:553S–559SPubMed

41.

Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A (2005) Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 19:385–391PubMedCrossRef

42.

Blomstrand E (2006) A role for branched-chain amino acids in reducing central fatigue. J Nutr 136(2):544S–547SPubMed

43.

Newsholme EA, Blomstrand E (1995) Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Adv Exp Med Biol 384:315–320PubMedCrossRef

44.

Chaouloff F, Elghozi JL, Guezennec Y, Laude D (1985) Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5-hydroxytryptamine metabolism of the rat. Br J Pharmacol 86:33–41PubMedCrossRef

45.

Blomstrand E, Hassmén P, Newsholme EA (1991) Effect of branched-chain amino acid supplementation on mental performance. Acta Physiol Scand 143:225–226PubMedCrossRef

46.

Mittleman KD, Ricci MR, Bailey SP (1998) Branched-chain amino acids prolong exercise during heat stress in men and women. Med Sci Sports Exerc 30:83–91PubMed

47.

Strüder HK, Hollmann W, Platen P, Donike M, Gotzmann A, Weber K (1998) Influence of paroxetine, branched-chain amino acids and tyrosine on neuroendocrine system responses and fatigue in humans. Horm Metab Res 30:188–194PubMedCrossRef

48.

Davis JM, Bailey SP (1997) Possible mechanisms of central nervous system fatigue during exercise. Med Sci Sports Exerc 29:45–57PubMed

49.

Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P (1997) Blunted serotonin-mediated activation of the hypothalamic–pituitary–adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 22:261–267PubMedCrossRef

50.

Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389–398PubMedCrossRef

51.

Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B et al (2007) Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 32:2384–2392PubMedCrossRef

52.

Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31:2121–2131PubMed

53.

Shanks N, Harbuz MS, Jessop DS, Perks P, Moore PM, Lightman SL (1998) Inflammatory disease as chronic stress. Ann N Y Acad Sci 840:599–607PubMedCrossRef

54.

Del Priore G, Gurski KJ, Warshal DP, Angel C, Dubeshter B (1995) Adrenal function following high-dose steroids in ovarian cancer patients. Gynecol Oncol 59:102–104PubMedCrossRef

55.

Morrow GR, Hickok JT, Andrews PL, Stern RM (2002) Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? Psychophysiology 39:491–495PubMedCrossRef

56.

Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulse HS, Müller J (2003) Assessment of the hypothalamus-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumour. J Clin Endocrinol Metab 88:3149–3154PubMedCrossRef

57.

Cleare AJ (2003) The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 24:236–252PubMed

58.

Petrovsky N, McNair P, Harrison LC (1998) Diurnal rhythms of proinflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 10:307–312PubMedCrossRef

59.

Vgontzas AN, Chrousos GP (2002) Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 31:15–36PubMedCrossRef

60.

McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52:89–99PubMedCrossRef

61.

Sephton S, Spiegel D (2003) Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17:321–328PubMedCrossRef

62.

Bower JE, Ganz PA, Dickerson SS, Dickerson SS, Petersen L, Aziz N et al (2005) Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30:92–100PubMedCrossRef

63.

Berger AM (1998) Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 25:51–62PubMed

64.

Mormont MC, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F (1998) Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 78:421–424PubMedCrossRef

65.

Giordano A, Calvani M, Petillo O, Carteni' M, Melone MR, Peluso G (2003) Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 90:170–186PubMedCrossRef

66.

Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142PubMedCrossRef

67.

Allman BL, Rice CL (2002) Neuromuscular fatigue and aging: central and peripheral factors. Muscle Nerve 25:785–796PubMedCrossRef

68.

Petrella JK, Kim JS, Tuggle SC, Hall SR, Bamman MM (2005) Age differences in knee extension power, contractile velocity, and fatigability. J Appl Physiol 98:211–220PubMedCrossRef

69.

Wilson MM, Morley JE (2003) Invited review: aging and energy balance. J Appl Physiol 95:1728–1736PubMed

70.

Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933:222–234PubMedCrossRef

71.

Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–1621PubMedCrossRef

72.

Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D et al (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 100:1920–1925PubMedCrossRef

73.

Dunn AJ, Wang J, Ando T (1999) Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461:117–127PubMedCrossRef

74.

Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN et al (2005) Catecholamine mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135:1295–1307PubMedCrossRef

75.

Bower JE, Ganz PA, Irwin MR, Arevalo JM, Cole SW (2011) Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signalling in breast cancer survivors with persistent fatigue. Brain Behav Immun 25:147–150PubMedCrossRef

76.

Luciani A, Jacobsen PB, Extermann M, Foa P, Marussi D, Overcash JA et al (2008) Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 31:424–430PubMedCrossRef

77.

Butt Z, Rao AV, Lai JS, Abernethy AP, Rosenbloom SK, Cella D (2010) Age-associated differences in fatigue among patients with cancer. J Pain Symptom Manage 40:217–223PubMedCrossRef

78.

Bergman H, Ferrucci L, Guralnik J, Hogan DB, Hummel S, Karunananthan S et al (2007) Frailty: an emerging research and clinical paradigm—issues and controversies. J Gerontol A Biol Sci Med Sci 62:731–737PubMedCrossRef

79.

Buchner DM, Wagner EH (1992) Preventing frail health. Clin Geriatr Med 8:1–17PubMed

80.

Fried LP, Walston J (2003) Frailty and failure to thrive. In: Hazzard WR, Blass JP, Ettinger WH (eds) Principles of geriatric medicine and gerontology. McGraw-Hill, New York, pp 1487–1502

81.

Siegel K, Lekas HM, Maheshwari D (2012) Causal attributions for fatigue by older adults with advanced cancer. J Pain Symptom Manage 44:52–63PubMedCrossRef

82.

Giacalone A, Blandino M, Talamini R, Bortolus R, Spazzapan S, Valentini M et al (2007) What elderly cancer patients want to know? Differences among elderly and young patients. Psycho-Oncology 16:365–370PubMedCrossRef

83.

Wu HS, McSweeney M (2001) Measurement of fatigue in people with cancer. Oncol Nurs Forum 28:1371–1384PubMed

84.

Minton O, Stone P (2009) A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20:17–25PubMedCrossRef

85.

Yellen SB, Cella DF, Webster K, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63–74PubMedCrossRef

86.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

87.

Knobel H, Loge JH, Brenne E, Fayers P, Hjermstad MJ, Kaasa S (2003) The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 17:664–672PubMed

88.

Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344PubMedCrossRef

89.

Giacalone A, Talamini R, Spina M, Fratino L, Spazzapan S, Tirelli U (2008) Can the caregiver replace his/her elderly cancer patient in the physician–patient line of communication? Support Care Cancer 16:1157–1162PubMedCrossRef

90.

Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC (2011) Psycho-stimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 41:761–767PubMedCrossRef

91.

Barsevick AM, Dudley W, Beck S, Sweeney C, Whitmer K, Nail L (2004) A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 100:1302–1310PubMedCrossRef

92.

Graydon JE, Bubela N, Irvine D, Vincent L (1995) Fatigue-reducing strategies used by patients receiving treatment for cancer. Cancer Nurs 18:23–28PubMedCrossRef

93.

Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev CD006145

94.

Dimeo FC (2001) Effects of exercise on cancer-related fatigue. Cancer 92:1689–1693PubMedCrossRef

95.

Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett M, Poniatowski B et al (2005) Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncol 14:464–477CrossRef

96.

Kangas M, Bovbjerg DH, Montgomery GH (2008) Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 134:700–741PubMedCrossRef

97.

Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev CD006953

98.

Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ (2007) Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26:660–667PubMedCrossRef

99.

Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C et al (2005) Study of etanercept, a tumour necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23:5950–5959PubMedCrossRef

100.

Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K et al (2004) A phase II study of etanercept (Enbrel), a tumour necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528–6534PubMedCrossRef

101.

Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA et al (2006) Assessment of tumour necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 24:1852–1859PubMedCrossRef

102.

103.

Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9:580–586PubMed

104.

Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA et al (2012) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 43:68–77PubMedCrossRef

105.

Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ et al (2010) Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-No5C7 Trial. J Clin Oncol 28:3673–3679PubMedCrossRef

106.

Yennurajalingam S, Palmer JL, Chacko R, Bruera E (2011) Factor associated with response to methylphenidate in advanced cancer patients. Oncologist 16:246–253PubMedCrossRef

107.

Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z et al (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38:650–662PubMedCrossRef

108.

Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Beunis H, Braganza S et al (2008) A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16:577–583PubMedCrossRef

109.

Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M et al (2010) A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116:3513–3520PubMedCrossRef

110.

Blackhall L, Petroni G, Shu J, Baum L, Farace E (2009) A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 12:433–439PubMedCrossRef

111.

Spatis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K (2009) Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23:325–331CrossRef

112.

Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J et al (2009) L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage 37:622–631PubMedCrossRef

113.

Esquedo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A (2011) Effectiveness of darbepoetin alfa in a color of oncology patients with chemotherapy-induced anemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in hemoglobin level. Clin Transl Oncol 13:341–347CrossRef

Title: Cancer-related fatigue in the elderly
Authors: A. Giacalone
D. Quitadamo
E. Zanet
M. Berretta
M. Spina
U. Tirelli
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-1897-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

FIT false-positives in colorectal cancer screening experience psychological distress up to 6 weeks after colonoscopy

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone

Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey

What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: an integrative overview of reviews

Cognitive interviewing of bereaved relatives to improve the measurement of health outcomes and care utilisation at the end of life in a mortality followback survey

Sublingually administered scopolamine for nausea in terminally ill cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer